Detection, screening, and diagnosis of HPV-associated cancers
First Claim
1. A method of assessing the risk for malignancy of a variety of cancers and carcinomas in a clinical sample from a human subject, comprising:
- providing a clinical sample from a source sample other than cervical sample;
conducting one or more detection assays on the clinical sample from the human subject using one or more anti-HPV antibodies; and
detecting the presence of HPV proteins present in the clinical sample to assess the risk of malignancy for the human subject.
3 Assignments
0 Petitions
Accused Products
Abstract
Embodiments of the invention provide methods, polyclonal antibodies, monoclonal antibodies, assays, and kits for detecting HPV infection, including infection by various HPV genotypes, early and/or late HPV-associated or HPV-specific proteins or antibodies. Monoclonal antibodies are used to detect oncogenic high risk and low risk HPV types in a single assay, which is not limited to assay type or format. Useful tools for specific detection of various HPV associated cancers are provided. HPV associated cancer biomarkers are identified and can be used in a screening method for early stage precancerous lesions as well as late stage cancer progression.
99 Citations
12 Claims
-
1. A method of assessing the risk for malignancy of a variety of cancers and carcinomas in a clinical sample from a human subject, comprising:
-
providing a clinical sample from a source sample other than cervical sample; conducting one or more detection assays on the clinical sample from the human subject using one or more anti-HPV antibodies; and detecting the presence of HPV proteins present in the clinical sample to assess the risk of malignancy for the human subject. - View Dependent Claims (2, 3, 4, 5, 6)
-
-
7. A method of detecting papillomavirus infection in a human subject, comprising:
obtaining a clinical sample from the human subject; and
conducting one or more immunological assays on the clinical sample from the human subject using lab-generated anti-HPV antibodies to detect the presence of HPV infection from the presence of HPV proteins in the clinical sample and access the risk for malignancy of non-cervical cancer.- View Dependent Claims (8, 9, 10, 11, 12)
Specification